Brief: First Patient Enrolled Into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial With Rgn-259
13/04/2023 14:26
April 13 (Reuters) - RegeneRx Biopharmaceuticals Inc
RGRX.PK :
* FIRST PATIENT ENROLLED INTO U.S. PHASE 3 NEUROTROPHIC
KERATITIS
CLINICAL TRIAL WITH RGN-259
Source text for Eikon: ID:nPn49H8cJa
Further company coverage: RGRX.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RegeneRx Biopharmaceuticals
See all newsBrief: Regenerx Effects Reverse Stock Split, Terminates SEC Reporting Obligations
Brief: Regenerx Receives Stockholder Approval For Reverse Stock Split
Brief: First Patient Enrolled Into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial With Rgn-259
Brief: RegeneRx Publishes RGN-259 Phase 3 Clinical Trial Results
Brief: Regenerx Reports Topline Results Of Arise-3 Dry Eye Trial